Inovio Pharmaceuticals Inc (INO)

[chmcnfunds]

Q3 2017 Inovio Pharmaceuticals Inc Earnings Call

BLUE BELL Nov 17, 2017 (Thomson StreetEvents) -- Edited Transcript of Inovio Pharmaceuticals Inc earnings conference call or presentation Wednesday, November 8, 2017 at 9:30:00pm GMT

TEXT version of Transcript

================================================================================

Corporate Participants

================================================================================

* J. Joseph Kim

Inovio Pharmaceuticals, Inc. - CEO, President & Director

* Jeffrey C. Richardson

Inovio Pharmaceuticals, Inc. - VP of Strategic Relations

* Peter D. Kies

Inovio Pharmaceuticals, Inc. - CFO

================================================================================

Conference Call Participants

================================================================================

* Charles Cliff Duncan

Piper Jaffray Companies, Research Division - MD and Senior Research Analyst

* Matthew Joseph Eckler

RBC Capital Markets, LLC, Research Division - Analyst

* Yi Chen

H.C. Wainwright & Co, LLC, Research Division - MD of Equity Research & Senior Healthcare Analyst

================================================================================

Presentation

--------------------------------------------------------------------------------

Operator [1]

--------------------------------------------------------------------------------

Greetings, and welcome to the Inovio Pharmaceuticals, Inc. Third Quarter 2017 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Mr. Jeff Richardson. Thank you. Mr. Richardson, you may begin.

--------------------------------------------------------------------------------
TO LONG TO POST, BUT THIS SEGMENT IS INTERESTING:

"Let me remind you that Inovio was, and remains, the first organization in the world to report positive Zika vaccine data from a clinical study. We've also posted similar encouraging HIV, Ebola and MERS vaccine data consistently posting greater than 90% immune response rates across the vaccine trials, all rising from our product development engine or DNA vaccine platform.

A second Phase I Zika vaccine study, now fully enrolled, with 160 participants in Puerto Rico, is designed with a placebo control to explore a potential trend towards clinical efficacy. We expect to have this data in 2018.

Because our DNA vaccine can be rapidly designed and manufactured, our products are well positioned to meet major public health challenges. Fully funded via a previous $3.5 million grant from the NIH and working with our collaborators at U.S. Army, Inovio last month announced the publication of a study with -- in which our vaccine provided 100% protection for nonhuman primates challenged with a lethal dose of the Lassa fever virus, a virulin haemorrhagic virus similar to Ebola, which infects approximately 300,000 people annually."
___________________________________________________

https://finance.yahoo.com/news/edited-transcript-ino-earnings-conference-034026462.html

INO